JP2001509168A - 血管新生を誘導するためのアデノウイルスベクターの多部位送達 - Google Patents
血管新生を誘導するためのアデノウイルスベクターの多部位送達Info
- Publication number
- JP2001509168A JP2001509168A JP53224998A JP53224998A JP2001509168A JP 2001509168 A JP2001509168 A JP 2001509168A JP 53224998 A JP53224998 A JP 53224998A JP 53224998 A JP53224998 A JP 53224998A JP 2001509168 A JP2001509168 A JP 2001509168A
- Authority
- JP
- Japan
- Prior art keywords
- angiogenesis
- vector
- tissue
- target tissue
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000013598 vector Substances 0.000 title claims abstract description 191
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 131
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 78
- 238000000034 method Methods 0.000 claims abstract description 90
- 230000001939 inductive effect Effects 0.000 claims abstract description 80
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 37
- 239000008280 blood Substances 0.000 claims abstract description 20
- 210000004369 blood Anatomy 0.000 claims abstract description 19
- 206010053648 Vascular occlusion Diseases 0.000 claims abstract description 16
- 239000003937 drug carrier Substances 0.000 claims abstract description 16
- 230000010412 perfusion Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 208000021331 vascular occlusion disease Diseases 0.000 claims abstract description 16
- 230000001965 increasing effect Effects 0.000 claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 6
- 208000037906 ischaemic injury Diseases 0.000 claims abstract description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 68
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 67
- 210000002216 heart Anatomy 0.000 claims description 23
- 238000012217 deletion Methods 0.000 claims description 21
- 230000037430 deletion Effects 0.000 claims description 21
- 108700039887 Essential Genes Proteins 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 14
- 210000000056 organ Anatomy 0.000 claims description 10
- 230000008081 blood perfusion Effects 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 140
- 241001465754 Metazoa Species 0.000 description 80
- 108090000623 proteins and genes Proteins 0.000 description 43
- 230000014509 gene expression Effects 0.000 description 41
- 238000002347 injection Methods 0.000 description 37
- 239000007924 injection Substances 0.000 description 37
- 230000006870 function Effects 0.000 description 26
- 108010082117 matrigel Proteins 0.000 description 25
- 230000006698 induction Effects 0.000 description 24
- 230000000302 ischemic effect Effects 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 210000004165 myocardium Anatomy 0.000 description 21
- 230000036961 partial effect Effects 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- 210000003141 lower extremity Anatomy 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 238000012546 transfer Methods 0.000 description 16
- 210000004351 coronary vessel Anatomy 0.000 description 15
- 238000001356 surgical procedure Methods 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 14
- 239000004005 microsphere Substances 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 12
- 208000028867 ischemia Diseases 0.000 description 12
- 241000701022 Cytomegalovirus Species 0.000 description 11
- 230000002107 myocardial effect Effects 0.000 description 11
- 230000008719 thickening Effects 0.000 description 11
- 230000002792 vascular Effects 0.000 description 11
- 210000000577 adipose tissue Anatomy 0.000 description 10
- 210000000709 aorta Anatomy 0.000 description 10
- 210000002027 skeletal muscle Anatomy 0.000 description 10
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 108010005774 beta-Galactosidase Proteins 0.000 description 9
- 102000058223 human VEGFA Human genes 0.000 description 9
- 230000002861 ventricular Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000001746 atrial effect Effects 0.000 description 8
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000002603 single-photon emission computed tomography Methods 0.000 description 8
- 238000002583 angiography Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 101710132601 Capsid protein Proteins 0.000 description 5
- 101710094648 Coat protein Proteins 0.000 description 5
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 5
- 101710125418 Major capsid protein Proteins 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 101710083689 Probable capsid protein Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 230000002491 angiogenic effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000036770 blood supply Effects 0.000 description 5
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 5
- 230000002612 cardiopulmonary effect Effects 0.000 description 5
- 238000002592 echocardiography Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 210000001087 myotubule Anatomy 0.000 description 5
- JFRJCQJVFMHZOO-QZHHGCDDSA-N n-(2-aminoethyl)-2-[4-[[2-[4-[[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]amino]phenyl]acetyl]amino]phenyl]acetamide Chemical compound C1=CC(CC(=O)NCCN)=CC=C1NC(=O)CC(C=C1)=CC=C1NC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 JFRJCQJVFMHZOO-QZHHGCDDSA-N 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- 210000003752 saphenous vein Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 210000005166 vasculature Anatomy 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000006427 angiogenic response Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000009434 installation Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 210000003516 pericardium Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 230000003872 anastomosis Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 108010011903 peptide receptors Proteins 0.000 description 3
- 102000014187 peptide receptors Human genes 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 238000002627 tracheal intubation Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000008076 Angiogenic Proteins Human genes 0.000 description 2
- 108010074415 Angiogenic Proteins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 241000726306 Irus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000003489 abdominal muscle Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000001174 endocardium Anatomy 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 210000003090 iliac artery Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000001349 mammary artery Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- -1 more preferably Proteins 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000009707 neogenesis Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 238000011158 quantitative evaluation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 238000007390 skin biopsy Methods 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 101710190943 Angiogenin-2 Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010057751 Post procedural discharge Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- GDSCFOSHSOWNDL-UHFFFAOYSA-N Zolasepam Chemical compound N=1CC(=O)N(C)C(N(N=C2C)C)=C2C=1C1=CC=CC=C1F GDSCFOSHSOWNDL-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 210000005248 left atrial appendage Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- IPSIPYMEZZPCPY-UHFFFAOYSA-N new fuchsin Chemical compound [Cl-].C1=CC(=[NH2+])C(C)=CC1=C(C=1C=C(C)C(N)=CC=1)C1=CC=C(N)C(C)=C1 IPSIPYMEZZPCPY-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 1
- 229960005457 pancuronium Drugs 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000003105 phrenic nerve Anatomy 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000002321 radial artery Anatomy 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003303 reheating Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- XZNXVSDNACTASG-RZNNTOFGSA-M sodium;3,5-diacetamido-2,4,6-triiodobenzoate;3,5-diacetamido-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound [Na+].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I XZNXVSDNACTASG-RZNNTOFGSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000001321 subclavian vein Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 1
- 229940032712 succinylcholine Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013175 transesophageal echocardiography Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 229960001366 zolazepam Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.標的組織への血液の灌流のレベルを増進させる方法であって、 (a)医薬上許容される担体および(b)血管形成誘導ペプチドをコードするDNAを 含むアデノウイルスベクターを含有する医薬組成物の一用量を、該組織への複数 回適用を介して投与し、該組織への該血液の灌流のレベルを増進させる方法。 2.虚血性損傷を病んでいるか、あるいは病む危険性のある標的組織の処置方法 であって、 (a)医薬上許容される担体および(b)血管形成誘導ペプチドをコードするDNAを 含むアデノウイルスベクターを含有する医薬組成物の一用量を、該組織への複数 回適用を介して投与し、該用量により該組織において治療または予防効果をもた らす方法。 3.標的組織における血管新生を誘導する方法であって、 (a)医薬上許容される担体および(b)血管形成誘導ペプチドをコードするDNAを 含むアデノウイルスベクターを含有する医薬組成物の一用量を、該組織への複数 回適用を介して投与し、該組織において血管新生を誘導する方法。 4.血管閉塞に冒されているか、あるいは冒される危険性のある標的組織におけ る側副血管形成を誘導する方法であって、 (a)医薬上許容される担体および(b)血管形成誘導ペプチドをコードするDNAを 含むアデノウイルスベクターを含有する医薬組成物の一用量を、該組織へ投与し 、該アデノウイルスベクターを該側副血管形成のための起点、終点およびそれら の間の領域を含む領域に接触させる方法。 5.該標的組織がはっきりと区別される器官の中にある請求の範囲1〜4のいず れかの方法。 6.該はっきりと区別される器官が心臓である請求の範囲5の方法。 7.該心臓がヒト心臓である請求の範囲6の方法。 8.該複数回適用の各々が該標的組織の約0.5〜15cm3に投与される請求 の範囲1〜7のいずれかの方法。 9.該複数回適用のすべてが約10分以内に投与される請求の範囲1〜8のいず れかの方法。 10.該複数回適用が実質的に同時である請求の範囲1〜9のいずれかの方法。 11.該血管形成誘導ペプチドが、VEGF121、VEGF145、VEGF165お よびVEGF189からなる群より選択される請求の範囲1〜10のいずれかの方 法。 12.該ベクターが、アデノウイルスゲノムのE1領域の少なくとも1つの不可 欠な遺伝子機能を欠損する請求の範囲1〜11のいずれかの方法。 13.該ベクターがE3領域の一部を欠損する請求の範囲1〜12のいずれかの 方法。 14.該ベクターが、E1a領域の少なくとも一部の欠失、E1b領域の少なく とも一部の欠失およびE3領域の少なくとも一部の欠失を有する請求の範囲1〜 13のいずれかの方法。 15.該ベクターが、アデノウイルスゲノムのE4領域の少なくとも1つの不可 欠な遺伝子機能を欠損する請求の範囲1〜14のいずれかの方法。 16.該ベクターが、E1領域の少なくとも一部の欠失、E3領域の少なくとも 一部の欠失およびE4領域の少なくとも一部の欠失を有する請求の範囲1〜15 のいずれかの方法。 17.該DNAが、該アデノウイルスベクターの該アデノウイルスゲノムにおい て右から左の方向である請求の範囲1〜16のいずれかの方法。 18.該DNAがアデノウイルスゲノムのE1領域内に位置する請求の範囲17 の方法。 19.該組織が血管閉塞に冒されているか、あるいは冒される危険性のある請求 の範囲1〜18のいずれかの方法。 20.該用量が該標的組織に生体外で投与される請求の範囲1〜19のいずれか の方法。 21.該用量が該標的組織にインビボで投与される請求の範囲1〜19のいずれ かの方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3660197P | 1997-01-29 | 1997-01-29 | |
US08/801,352 US5846225A (en) | 1997-02-19 | 1997-02-19 | Gene transfer therapy delivery device and method |
US7115698P | 1998-01-13 | 1998-01-13 | |
US60/036,601 | 1998-01-13 | ||
US60/071,156 | 1998-01-13 | ||
US08/801,352 | 1998-01-13 | ||
PCT/US1998/001638 WO1998032859A1 (en) | 1997-01-29 | 1998-01-29 | Multiple site delivery of adenoviral vector for the induction of angiogenesis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001509168A true JP2001509168A (ja) | 2001-07-10 |
JP2001509168A5 JP2001509168A5 (ja) | 2005-09-08 |
Family
ID=27365066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53224998A Ceased JP2001509168A (ja) | 1997-01-29 | 1998-01-29 | 血管新生を誘導するためのアデノウイルスベクターの多部位送達 |
Country Status (16)
Country | Link |
---|---|
US (2) | US6518255B2 (ja) |
EP (1) | EP1012291B1 (ja) |
JP (1) | JP2001509168A (ja) |
KR (1) | KR20000070572A (ja) |
AT (1) | ATE279518T1 (ja) |
AU (1) | AU745409B2 (ja) |
BR (1) | BR9806819A (ja) |
CA (1) | CA2278621A1 (ja) |
DE (1) | DE69827021T2 (ja) |
HU (1) | HUP0001964A3 (ja) |
IL (1) | IL131021A0 (ja) |
MX (1) | MXPA99006993A (ja) |
NO (1) | NO993669L (ja) |
NZ (1) | NZ336838A (ja) |
PL (1) | PL334902A1 (ja) |
WO (1) | WO1998032859A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016506911A (ja) * | 2013-01-17 | 2016-03-07 | メディツィーニシェ・ホーホシューレ・ハノーファーMedizinische Hochschule Hannover | 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238673B2 (en) | 1989-03-31 | 2007-07-03 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
AU745409B2 (en) * | 1997-01-29 | 2002-03-21 | Cornell Research Foundation Inc. | Multiple site delivery of adenoviral vector for the induction of angiogenesis |
US6775574B1 (en) * | 1997-11-07 | 2004-08-10 | Medtronic, Inc. | Method and system for myocardial infarction repair |
US6251079B1 (en) | 1998-09-30 | 2001-06-26 | C. R. Bard, Inc. | Transthoracic drug delivery device |
ES2316194T3 (es) * | 1998-10-28 | 2009-04-01 | Cornell Research Foundation, Inc. | Metodos para la regulacion de la angiogenesis y la integridad vascular utilizando los ligandos bdnf, nt-3 y nt-4. |
AU5646300A (en) * | 1999-02-10 | 2000-08-29 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods of stimulating angiogenesis |
US6440945B1 (en) * | 1999-05-27 | 2002-08-27 | Instituto Dermopatico Dell'immacolata | Method of inducing angiogenesis in nonis chemic skeletal muscle |
WO2000078357A2 (en) * | 1999-06-18 | 2000-12-28 | The Collaborative Group, Ltd. | Hyaluronic acid film and matrix for sustained gene transfer |
EP1067190A1 (en) * | 1999-07-09 | 2001-01-10 | Introgene B.V. | Gene therapy for enhancing and/or inducing angiogenesis |
EP1199992A1 (en) | 1999-08-05 | 2002-05-02 | Cornell Research Foundation, Inc. | Gene therapy platformed needle and method of administering a therapeutic solution to a heart |
FR2799465B1 (fr) * | 1999-10-12 | 2004-02-13 | Centre Nat Rech Scient | Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire |
NZ546670A (en) * | 1999-11-05 | 2009-02-28 | Univ California | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
US6329348B1 (en) | 1999-11-08 | 2001-12-11 | Cornell Research Foundation, Inc. | Method of inducing angiogenesis |
US6508802B1 (en) | 2000-05-23 | 2003-01-21 | Cornell Research Foundation, Inc. | Remote sensing gene therapy delivery device and method of administering a therapeutic solution to a heart |
US6939540B1 (en) | 2000-07-31 | 2005-09-06 | Cornell Research Foundation, Inc. | Method of enhancing bone density |
NZ518077A (en) * | 2000-08-04 | 2003-11-28 | Human Genome Sciences Inc | Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease |
US20040009940A1 (en) * | 2000-10-20 | 2004-01-15 | Coleman Michael E. | Gene delivery formulations and methods for treatment of ischemic conditions |
US6793918B2 (en) * | 2000-11-01 | 2004-09-21 | Ludwig Institute For Cancer Research | In vivo stimulation of angiogenic activity |
JP2005501802A (ja) * | 2001-01-23 | 2005-01-20 | ボストン サイエンティフィック コーポレイション | 虚血心筋を処置するための限局性心筋注入方法 |
AR027161A1 (es) | 2001-05-15 | 2003-03-19 | Bio Sidus S A | Metodo para inducir la proliferacion neovascular y regeneracion tisular |
US20030157064A1 (en) * | 2001-11-09 | 2003-08-21 | Pascal Neuville | Chimeric promoters for controlling expression in muscle cells |
JP2006514929A (ja) * | 2002-11-15 | 2006-05-18 | ジェンベク、インコーポレイティッド | 冠動脈疾患の治療 |
BRPI0509620A (pt) | 2004-04-05 | 2007-09-18 | Univ California | modulação de nkg2d |
EP3072522B1 (en) | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
US7751883B2 (en) | 2006-04-25 | 2010-07-06 | Eugenio Picano | System and method for promoting coronary angiogenesis |
WO2007136673A2 (en) * | 2006-05-19 | 2007-11-29 | Medistem Laboratories, Inc. | Treatment of disc degenerative disease and compositions for same |
US8983570B2 (en) | 2007-03-27 | 2015-03-17 | Cardiovascular Biotherapeutics, Inc. | Therapeutic angiogenesis for treatment of the spine |
US11224635B2 (en) | 2007-03-27 | 2022-01-18 | Venturis Thereuptics, Inc. | Therapeutic angiogenesis for treatment of the spine and other tissues |
CN101998965B (zh) | 2007-11-01 | 2014-03-12 | 安斯泰来制药有限公司 | 免疫抑制性多肽与核酸 |
US8409147B2 (en) * | 2009-08-22 | 2013-04-02 | Joseph Wayne Kraft | Rapid local anesthesia linear injection device |
US8088108B2 (en) * | 2009-08-22 | 2012-01-03 | Joseph Wayne Kraft | Rapid local anesthesia injection cone |
WO2011026041A2 (en) | 2009-08-28 | 2011-03-03 | The Cleveland Clinic Foundation | Sdf-1 delivery for treating ischemic tissue |
US20150206302A1 (en) * | 2012-08-30 | 2015-07-23 | Emory University | Systems, methods and computer readable storage media storing instructions for integrating fluoroscopy venogram and myocardial images |
WO2016134293A1 (en) | 2015-02-20 | 2016-08-25 | Baylor College Of Medicine | p63 INACTIVATION FOR THE TREATMENT OF HEART FAILURE |
EP3329930A1 (en) | 2016-12-05 | 2018-06-06 | Nuritas Limited | Pharmaceuctical compositions |
AU2017373651B2 (en) | 2016-12-05 | 2022-03-10 | Nuritas Limited | Compositions comprising peptide wkdeagkplvk |
EP4041192A4 (en) * | 2019-10-09 | 2023-11-08 | Xylocor Therapeutics, Inc. | EPICARDIAL DELIVERY OF GENE THERAPY |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US510413A (en) | 1893-12-12 | Drainage-tube | ||
US2551902A (en) | 1948-09-10 | 1951-05-08 | Arthur Schaffer | Dehorning fluid ejector |
US2670673A (en) | 1950-07-17 | 1954-03-02 | Joyce A Gordon | Fluid injecting device |
US3467096A (en) | 1966-04-12 | 1969-09-16 | Ferrell S Horn | Multiple hypodermic syringe arrangement |
FR1584474A (ja) | 1968-02-20 | 1969-12-26 | ||
US3572336A (en) | 1968-04-30 | 1971-03-23 | Daniel R Hershberg | Syringe |
US4150669A (en) | 1977-03-16 | 1979-04-24 | Alvaro Latorre | Apparatus for effecting and enhancing an erection |
US4167179A (en) | 1977-10-17 | 1979-09-11 | Mark Kirsch | Planar radioactive seed implanter |
US5335670A (en) | 1986-04-18 | 1994-08-09 | Henry Fishman | Allergy testing method and apparatus |
JPS6438100A (en) | 1987-07-31 | 1989-02-08 | Toray Industries | Vascular endothelial cell growth factor |
JPH02117698A (ja) | 1988-10-27 | 1990-05-02 | Toray Ind Inc | 血管内皮細胞成長因子 |
US5240848A (en) | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
JPH02279698A (ja) | 1989-04-20 | 1990-11-15 | M K Medical:Kk | 血管内皮細胞成長因子及びその製造方法 |
US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
EP0399816B1 (en) | 1989-05-24 | 1995-12-20 | Merck & Co. Inc. | Purification and characterization of a glioma-derived growth factor |
US5219739A (en) * | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
JPH03178996A (ja) | 1989-12-06 | 1991-08-02 | Makoto Goto | 成長因子 |
US6228844B1 (en) * | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
EP0476983B1 (en) | 1990-09-21 | 2000-03-15 | Merck & Co. Inc. | Vascular endothelial cell growth factor II |
DE69229454T2 (de) | 1991-03-28 | 2000-01-05 | Merck & Co Inc | Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors |
US5244460A (en) | 1991-11-27 | 1993-09-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method to foster myocardial blood vessel growth and improve blood flow to the heart |
EP0550296A3 (en) | 1991-11-28 | 1993-12-29 | Terumo Corp | Vascular endothelial cells growth factor |
US5290258A (en) | 1992-07-27 | 1994-03-01 | Genesis Industries, Inc. | Syringe for administering sequentially multiple doses of a medicament |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
ES2249762T3 (es) | 1994-03-08 | 2006-04-01 | Human Genome Sciences, Inc. | Factor de crecimiento del endotelio vascular 2. |
US5851806A (en) * | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
US5417683A (en) | 1994-07-13 | 1995-05-23 | Shiao; I-Shen | Mini-graft hair implanting device for implanting multiple clumps of hair follicles at one time |
JPH10507758A (ja) * | 1994-10-19 | 1998-07-28 | ジェネティック セラピー,インコーポレイテッド | アデノウイルスおよび免疫抑制剤同時反復投与を伴う遺伝子治療 |
US5792453A (en) * | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
AU745409B2 (en) * | 1997-01-29 | 2002-03-21 | Cornell Research Foundation Inc. | Multiple site delivery of adenoviral vector for the induction of angiogenesis |
US5846225A (en) | 1997-02-19 | 1998-12-08 | Cornell Research Foundation, Inc. | Gene transfer therapy delivery device and method |
JP3371331B2 (ja) * | 1998-12-14 | 2003-01-27 | セイコーエプソン株式会社 | インクジェット式記録ヘッドおよびその製造方法 |
-
1998
- 1998-01-29 AU AU62530/98A patent/AU745409B2/en not_active Ceased
- 1998-01-29 DE DE69827021T patent/DE69827021T2/de not_active Expired - Fee Related
- 1998-01-29 HU HU0001964A patent/HUP0001964A3/hu unknown
- 1998-01-29 JP JP53224998A patent/JP2001509168A/ja not_active Ceased
- 1998-01-29 KR KR1019997006818A patent/KR20000070572A/ko not_active Application Discontinuation
- 1998-01-29 MX MXPA99006993A patent/MXPA99006993A/es unknown
- 1998-01-29 PL PL98334902A patent/PL334902A1/xx unknown
- 1998-01-29 WO PCT/US1998/001638 patent/WO1998032859A1/en active IP Right Grant
- 1998-01-29 EP EP98904730A patent/EP1012291B1/en not_active Expired - Lifetime
- 1998-01-29 CA CA002278621A patent/CA2278621A1/en not_active Abandoned
- 1998-01-29 IL IL13102198A patent/IL131021A0/xx unknown
- 1998-01-29 BR BR9806819-9A patent/BR9806819A/pt not_active IP Right Cessation
- 1998-01-29 NZ NZ336838A patent/NZ336838A/en unknown
- 1998-01-29 AT AT98904730T patent/ATE279518T1/de not_active IP Right Cessation
-
1999
- 1999-07-19 US US09/357,010 patent/US6518255B2/en not_active Expired - Lifetime
- 1999-07-28 NO NO993669A patent/NO993669L/no not_active Application Discontinuation
-
2003
- 2003-01-14 US US10/341,679 patent/US20030103943A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016506911A (ja) * | 2013-01-17 | 2016-03-07 | メディツィーニシェ・ホーホシューレ・ハノーファーMedizinische Hochschule Hannover | 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤 |
JP2020203894A (ja) * | 2013-01-17 | 2020-12-24 | メディツィーニシェ・ホーホシューレ・ハノーファーMedizinische Hochschule Hannover | 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
IL131021A0 (en) | 2001-01-28 |
NO993669L (no) | 1999-09-27 |
NO993669D0 (no) | 1999-07-28 |
US20010041679A1 (en) | 2001-11-15 |
CA2278621A1 (en) | 1998-07-30 |
US6518255B2 (en) | 2003-02-11 |
KR20000070572A (ko) | 2000-11-25 |
HUP0001964A3 (en) | 2002-01-28 |
DE69827021D1 (de) | 2004-11-18 |
PL334902A1 (en) | 2000-03-27 |
EP1012291B1 (en) | 2004-10-13 |
AU745409B2 (en) | 2002-03-21 |
US20030103943A1 (en) | 2003-06-05 |
EP1012291A1 (en) | 2000-06-28 |
BR9806819A (pt) | 2000-05-09 |
HUP0001964A2 (hu) | 2000-10-28 |
WO1998032859A1 (en) | 1998-07-30 |
ATE279518T1 (de) | 2004-10-15 |
AU6253098A (en) | 1998-08-18 |
MXPA99006993A (es) | 2005-06-01 |
NZ336838A (en) | 2002-04-26 |
DE69827021T2 (de) | 2005-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001509168A (ja) | 血管新生を誘導するためのアデノウイルスベクターの多部位送達 | |
JP3961019B2 (ja) | 遺伝子転移媒介の血管形成療法 | |
EP1017421B1 (en) | Use of adenoviral vectors expressing VEGF or PDGF FOR HEALING TISSUE DEFECTS AND INDUCING HYPERVASCULARITY IN MAMMALIAN TISSUE | |
Schwarz et al. | Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat—angiogenesis and angioma formation | |
EP1232759A1 (en) | Gene transfer-mediated angiogenesis therapy | |
US20160250290A1 (en) | Gene therapy for diabetic ischemic disease | |
KR102376245B1 (ko) | Vegf-a 폴리펩타이드를 인코딩하는 변형된 rna, 이와 관련된 제제 및 용도 | |
Li et al. | Targeted miR-21 loaded liposomes for acute myocardial infarction | |
Lee et al. | Cardiac gene transfer by intracoronary infusion of adenovirus vector—mediated reporter gene in the transplanted mouse heart | |
Funatsu et al. | Therapeutic angiogenesis in the ischemic canine heart induced by myocardial injection of naked complementary DNA plasmid encoding hepatocyte growth factor | |
US6329348B1 (en) | Method of inducing angiogenesis | |
JP2002502885A (ja) | 増強された遺伝子送達のための、核酸および血管作用性薬剤の組合せ | |
US20050191278A1 (en) | Coronary artery disease treatment | |
Iwatate et al. | Effects of in vivo gene transfer of fibroblast growth factor-2 on cardiac function and collateral vessel formation in the microembolized rabbit heart | |
WO2011024480A1 (ja) | 血管新生療法用医薬組成物 | |
AU2006235836A1 (en) | Gene transfer-mediated angiogenesis therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050121 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080401 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080826 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081014 |